Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Guoguang Ma

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|July 12, 2024
Variable Duration Trial as an Alternative Design for Continuous EndpointsJitendra Ganju, Julie Guoguang Ma
Cancer|June 24, 2005
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trialsRichard J Gralla, Ronald de Wit, Jorn Herrstedt, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|July 12, 2024
Variable Duration Trial as an Alternative Design for Continuous EndpointsJitendra Ganju, Julie Guoguang Ma
Cancer|June 24, 2005
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trialsRichard J Gralla, Ronald de Wit, Jorn Herrstedt, et al.
Pageof 1